A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3) (American Journal of Hematology, 2022)

(untitled) - Daver, N; Liu, K; Werneke, S; Rustia, E; Ramsingh, G; Paresh, V